GlaxoSmithKline Consumer Healthcare (GSK), the maker of Savlon, is extending the brand’s offering with the launch of Savlon Dual Action Gel to add to its existing range of antiseptic products.
Savlon Dual Action Gel has the added benefit of an anaesthetic. It is designed to attract consumers looking for antiseptic products with enhanced features and aims to increase basket spend.
The first aid category is worth £98 million and Savlon holds 14.8% value share in this category, being the leader within the antiseptic cream and liquid formats.
The Savlon range currently includes antiseptic cream, wound wash, antiseptic spray, healing gel, bites and stings pain relief gel and various plasters.
Savlon Dual Action Gel complements the existing range as its active ingredients are specially formulated to provide relief of pain, itching, irritation and antiseptic protection.
Sonila Troka, Senior Brand Manager for Savlon at GSK, said: “With a heritage of over 60 years, Savlon remains a market-leader in the antiseptic cream and liquids format with 30% market share.
"The launch of Savlon Dual Action Gel helps consumers remain prepared for when they want relief of pain and antiseptic protection whilst reinforcing Savlon’s three step first aid process of ‘Cleanse, Treat and Protect’." For more information www.gsk.com
 

LEAVE A REPLY